New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening
Portfolio Pulse from
BD (Becton, Dickinson and Company) announced that its BD Onclarity™ HPV Assay has been included in the ASCCP's new cervical cancer screening guidelines. The assay is noted for identifying more high-risk HPV types than any other test.
January 13, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BD's Onclarity™ HPV Assay has been included in the ASCCP's new guidelines, enhancing its market position by identifying more high-risk HPV types than competitors.
The inclusion of BD's Onclarity™ HPV Assay in the ASCCP guidelines is a significant endorsement, likely to increase demand and market share. This positions BD as a leader in HPV testing, potentially driving short-term stock price appreciation.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90